You're reading everything related to:
Key Insights From The Pharmaceutical Cannabis Report
Key Insights From CBD: The Consumer Report
CBD: The Consumer Report is the latest release in the suite of Prohibition Partners’ market-leading consumer research reports, providing proprietary data on over 15,000 adults from seven key global markets,...
Synthetic cannabinoid firm’s stock tanks 77% after failed clinical trials
Corbus Pharmaceuticals, one of the leaders in the pharmaceutical cannabinoid industry takes a hit as their lead drug fails in advanced clinical trials.
Australian medical cannabis approvals rising despite COVID-19 disruptions
After a quarter of stalled growth, approvals for cannabis-based medicines via the SAS-B route is now accelerating once more.
Product testing in Australia reveals inconsistencies over cannabinoid potency
Last Friday, Australian regulator TGA published test results on the most common medical cannabis products sold in Australia. Results, which showed 23% of products had cannabinoid levels which differed from...
Key Insights from The Oceania Cannabis Report: Second Edition
The Oceania Cannabis Report: Second Edition is the most extensive review of the cannabis sector in Australia, New Zealand and the surrounding islands. Launched last week, the report offers an...